These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25109842)

  • 21. Epilepsy: Vigabatrin treatment and visual field loss.
    Chiron C; Dulac O
    Nat Rev Neurol; 2011 Apr; 7(4):189-90. PubMed ID: 21364521
    [No Abstract]   [Full Text] [Related]  

  • 22. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visual field defect associated with vigabatrin: observational cohort study.
    Wilton LV; Stephens MD; Mann RD
    BMJ; 1999 Oct; 319(7218):1165-6. PubMed ID: 10541505
    [No Abstract]   [Full Text] [Related]  

  • 24. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 25. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
    Giordano L; Valseriati D; Vignoli A; Morescalchi F; Gandolfo E
    Neurol Sci; 2000 Jun; 21(3):185-6. PubMed ID: 11076009
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 27. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
    Comaish IF; Gorman C; Galloway NR
    BMJ; 2000 May; 320(7246):1403; author reply 1404. PubMed ID: 10858054
    [No Abstract]   [Full Text] [Related]  

  • 28. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
    Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
    Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
    [No Abstract]   [Full Text] [Related]  

  • 30. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examining visual field defects in the paediatric population exposed to vigabatrin.
    Spencer EL; Harding GF
    Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual field defects with vigabatrin: epidemiology and therapeutic implications.
    Kälviäinen R; Nousiainen I
    CNS Drugs; 2001; 15(3):217-30. PubMed ID: 11463129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 35. [Asymptomatic concentric visual field deficits and optic nerve atrophy].
    Mennel S; Schulze S; Meyer CH
    Ophthalmologe; 2006 Jun; 103(6):530-2. PubMed ID: 16132992
    [No Abstract]   [Full Text] [Related]  

  • 36. Screening of patients taking vigabatrin.
    Rebolleda G; Muñoz-Negrete FJ; Gutierrez C
    Ophthalmology; 2000 Jul; 107(7):1219-20. PubMed ID: 10889083
    [No Abstract]   [Full Text] [Related]  

  • 37. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
    Sorri I; Herrgård E; Viinikainen K; Pääkkönen A; Heinonen S; Kälviäinen R
    Epilepsy Res; 2005 Jun; 65(1-2):117-20. PubMed ID: 15941649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 39. Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.
    Schonstedt V; Stecher X; Venegas V; Silva C
    Neuroradiol J; 2015 Oct; 28(5):515-8. PubMed ID: 26306928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.